Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics
Lunai Bioworks (NASDAQ:LNAI) subsidiary BioSymetrics and academic partners published a Nature Communications study (Oct 16, 2025) reporting prognostic serum protein biomarkers for Duchenne muscular dystrophy (DMD).
The multi‑institutional analysis used the SomaScan proteomics platform on >700 longitudinal serum samples from European and U.S. cohorts and identified proteins including RGMA, ART3, and ANTXR2 that associate with motor performance and predict outcomes such as loss of ambulation and upper‑limb decline.
Authors say these minimally invasive biomarkers could refine clinical trial enrollment, improve stratification, and support more personalized patient management, while results were cross‑cohort validated and controlled for age and corticosteroid use.
Lunai Bioworks (NASDAQ:LNAI) consociata BioSymetrics e partner accademici hanno pubblicato uno studio su Nature Communications (16 ottobre 2025) riportando biomarcatori proteici plasmatici prognostici per la distrofia muscolare di Duchenne (DMD).
L'analisi multi‑istituzionale ha utilizzato la piattaforma proteomica SomaScan su oltre 700 campioni di siero longitudinali provenienti da coorti europee e statunitensi e ha identificato proteine tra cui RGMA, ART3 e ANTXR2 che si associano alla performance motoria e prevedono outcome come perdita dell'ambulation e declino dell'arto superiore.
Gli autori affermano che questi biomarcatori minimamente invasivi potrebbero raffinare l'inclusione negli studi clinici, migliorare la stratificazione e supportare una gestione del paziente più personalizzata, mentre i risultati sono stati validati cross‑coorte e controllati per età e uso di corticosteroidi.
Lunai Bioworks (NASDAQ:LNAI) filial BioSymetrics y socios académicos publicaron un estudio en Nature Communications (16 oct 2025) reportando biomarcadores proteicos séricos pronósticos para la distrofia muscular de Duchenne (DMD).
El análisis multicentral utilizó la plataforma proteómica SomaScan en más de 700 muestras de suero longitudinales de cohortes europeas y estadounidenses e identificó proteínas entre las que se encuentran RGMA, ART3 y ANTXR2 que se asocian con el rendimiento motor y predicen resultados como la pérdida de la ambulación y el declive de la extremidad superior.
Los autores dicen que estos biomarcadores mínimamente invasivos podrían refinar la selección de pacientes para ensayos clínicos, mejorar la estratificación y apoyar una gestión de pacientes más personalizada, mientras que los resultados fueron validados en múltiples cohortes y controlados por edad y uso de corticosteroides.
Lunai Bioworks (NASDAQ:LNAI) 자회사 BioSymetrics와 학계 파트너들은 Nature Communications 연구를 발표했고 (2025년 10월 16일) Duchenne 근육위축(DMD)에 대한 예후 혈청 단백질 바이오마커를 보고했습니다.
다기관 분석은 유럽 및 미국 코호트의 700건이 넘는 종단 혈청 샘플에 대해 SomaScan 단백질체 플랫폼을 사용했고 RGMA, ART3, ANTXR2를 포함한 단백질들이 운동 성능과 연관되며 보행 상실 및 상지 감소와 같은 결과를 예측한다고 밝혔습니다.
저자들은 이러한 최소 침습적 바이오마커가 임상 시험 등록을 세분화하고 계층화를 개선하며 보다 개인화된 환자 관리를 지원할 수 있다고 말합니다. 또한 결과는 교차 코호트로 검증되었고 연령 및 코르티코스테로이드 사용을 보정했습니다.
Lunai Bioworks (NASDAQ:LNAI) filiale BioSymetrics et partenaires académiques ont publié une étude dans Nature Communications (16 octobre 2025) rapportant des biomarqueurs protéiques sanguins pronostiques pour la dystrophie musculaire de Duchenne (DMD).
L'analyse multi‑institutionnelle a utilisé la plateforme protéomique SomaScan sur plus de 700 échantillons sériques longitudinaux provenant de cohortes européennes et américaines et a identifié des protéines dont RGMA, ART3 et ANTXR2 qui s’associent à la performance motrice et prédisent des résultats tels que la perte d’ambulation et le déclin du membre supérieur.
Les auteurs affirment que ces biomarqueurs peu invasifs pourraient affiner le recrutement des essais cliniques, améliorer la stratification et soutenir une prise en charge plus personnalisée des patients, tandis que les résultats ont été validés par plusieurs cohortes et ajustés en fonction de l’âge et de l’utilisation de corticostéroïdes.
Lunai Bioworks (NASDAQ:LNAI) Tochtergesellschaft BioSymetrics und akademische Partner veröffentlichten eine Nature Communications-Studie (16. Okt. 2025), die prädiktive Serumprotein-Biomarker für Duchenne-Muskeldystrophie (DMD) meldet.
Die multizentrische Analyse nutzte die SomaScan-Proteomics-Plattform auf über 700 longitudinalen Serumproben aus europäischen und US-Kohorten und identifizierte Proteine, darunter RGMA, ART3 und ANTXR2, die mit motorischer Leistung assoziiert sind und Ergebnisse wie Gehfähigkeitseinbußen und Verschlechterung der oberen Gliedmaßen vorhersagen.
Die Autoren sagen, dass diese minimal invasiven Biomarker die Teilnahme an klinischen Studien verfeinern, die Stratifikation verbessern und eine individuellere Patientenbetreuung unterstützen könnten, während die Ergebnisse kooperationsübergreifend validiert und für Alter sowie Kortikosteroideneinsatz kontrolliert wurden.
لوماي بيواوركس (NASDAQ:LNAI) شركة فرعية BioSymetrics وشركاء أكاديميون نشروا دراسة في Nature Communications (16 أكتوبر 2025) تقرّ بمؤشرات حيوية بلازمية تشخيصية لداء Duchenne العضلي التنكسي (DMD).
استخدم التحليل متعدد المؤسسات منصة SomaScan للبروتينات في أكثر من 700 عينة مصل طولية من فرق أوروبا والولايات المتحدة وحدّد بروتينات من ضمنها RGMA وART3 وANTXR2 ترتبط بالأداء الحركي وتتنبأ بنتائج مثل فقدان القدرة على المشي وتدهور الطرف العلوي.
يقول المؤلفون إن هذه المؤشرات الحيوية قليلة التدخل قد تُحَسن اختيار المشاركين في التجارب السريرية، وتحسن التصنيف وتدعم إدارة أكثر تخصيصاً للمرضى، بينما تم التحقق من النتائج عبر-cohorts والتحكم في العمر واستخدام الكورتيكوستيرويدات.
Lunai Bioworks (NASDAQ:LNAI) 的子公司 BioSymetrics 与学术伙伴发表了一项 Nature Communications 研究（2025年10月16日），报告了 Duchenne 肌营养不良症（DMD）的预测性血清蛋白生物标志物。
这项涉及多机构的分析在欧洲和美国队列的超过700份纵向血清样本上使用 SomaScan 蛋白质组平台，并鉴定出包括 RGMA、ART3 和 ANTXR2 在内的蛋白质，它们与运动表现相关并可预测如步态丧失和上肢衰退等结果。
作者表示，这些微创生物标志物可用于优化临床试验招募、改善分层并支持更个性化的患者管理，同时结果已跨队列验证并对年龄及皮质类固醎药物使用进行了控制。
- >700 longitudinal serum samples analyzed across two cohorts
- Identified specific prognostic proteins: RGMA, ART3, ANTXR2
- Cross‑cohort validation controlling for age and corticosteroid use
- No regulatory approval or clinical adoption described for the biomarkers
- Findings described as initial and require further validation before routine clinical use
Insights
Large-scale serum proteomics identified reproducible protein markers that predict functional decline in Duchenne muscular dystrophy.
The study used the SomaScan® platform on over 700 longitudinal serum samples across two independent cohorts and found proteins including RGMA, ART3, and ANTXR2 that correlate with motor performance and predict loss of ambulation and upper limb decline.
These biomarkers provide a minimally invasive way to quantify disease trajectory and could improve patient stratification in trials. Key dependencies include independent prospective validation, demonstration of added predictive value beyond clinical scales, and technical reproducibility across platforms and labs. Risks include cohort biases, confounding variables despite statistical control, and the need for regulatory qualification before clinical use.
Watch for replication in prospective natural history or interventional studies, cross‑platform concordance of the identified proteins, and formal regulatory biomarker submissions as the next clear milestones.
Published in Nature Communications, a new study uncovers critical protein biomarkers that predict functional decline in Duchenne Muscular Dystrophy (DMD), opening doors to more personalized care and improved clinical trials.
LEIDEN, THE NETHERLANDS, GAINESVILLE, FL, AND NEW YORK, NY, CA / ACCESS Newswire / October 16, 2025 / In a major advancement for Duchenne muscular dystrophy (DMD) research and patient care, a multi-institutional team led by investigators from Leiden University Medical Center, the University of Florida and BioSymetrics Inc (a subsidiary of Lunai Bioworks Inc.; NASDAQ:LNAI) has identified serum proteins that can serve as prognostic biomarkers in DMD. The study, published today in Nature Communications and supported by Parent Project Muscular Dystrophy (PPMD), analyzed over 700 longitudinal serum samples using the SomaScan® proteomics platform.
The research represents one of the most comprehensive proteomic efforts in DMD to date, integrating rich longitudinal data from two independent cohorts - one in Europe and one in the United States. Leveraging statistical modeling and cross-cohort validation, the team identified a set of proteins, including RGMA, ART3, and ANTXR2, that are not only associated with motor performance but also reliably predict disease progression, such as loss of ambulation and upper limb function.
"Monitoring progression of DMD patients in natural history studies and clinical trials has been historically done using clinical scales and timed tests that have been shown to be dependent on patients' motivation. This study shows that proteins in serum offer a valid alternative to monitor disease progression," said Dr. Pietro Spitali, an Associate Professor of human genetics at Leiden University Medical Center. "It has been a great pleasure to work on the project with this multidisciplinary team and I am looking forward to seeing how our data will be used by other groups to monitor their patients and to improve clinical trials design."
These findings are expected to contribute to earlier and more individualized interventions in clinical settings, and to refine enrollment and stratification strategies in clinical trials by identifying patients more likely to experience disease progression.
"Identifying robust, minimally invasive prognostic biomarkers in Duchenne muscular dystrophy has been a long-standing challenge for the field," said Dr. Glenn Walter, a professor of physiology and aging at the University of Florida. "This study represents a significant step forward, as these serum-based protein biomarkers not only enable the prediction of disease progression with a simple blood test but can also be integrated with other patient-specific data, including genetic and clinical information. The ability to combine these approaches will help facilitate more personalized management strategies, optimize clinical trial design, and ultimately improve outcomes for individuals living with DMD."
"We are greatly encouraged by these initial findings from this collaborative proteomics study," said Dr. Eric Camino, the vice president of research and clinical innovation at PPMD. "There is a critical need to identify biomarkers that can inform us about individual patient trajectories within such a heterogenous disease to enhance patient care and potentially impact therapy development."
BioSymetrics, a data science and AI company specializing in biomedical analytics, provided key analytical support and led the integration of clinical and proteomic data. Their advanced modeling capabilities enabled the discovery of statistically robust and biologically plausible biomarkers, while controlling for critical confounders such as age and corticosteroid use.
"We're proud to have played a role in this transformative project," said Dr. Gabe Musso, the Chief Scientific Officer of BioSymetrics. "This study is a great example of how collaboration between academia and industry can produce clinically actionable insights."
About the Study
Title: Large-scale serum protein biomarkers discovery associated with function and clinical milestones in Duchenne muscular dystrophy
Journal: Nature Communications
Publication Date: October 13th, 2025
Funding: Parent Project Muscular Dystrophy, Spieren voor Spieren and the U.S. NIH (NINDS, CTSI)
About Lunai Bioworks
Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.
Media Contact:
David Weinstein
Chief Executive Officer
305-918-1980
ir@lunaibioworks.com
http://www.lunaibioworks.com/
SOURCE: Lunai Bioworks Inc.
View the original press release on ACCESS Newswire
FAQ
What did Lunai Bioworks (LNAI) and partners announce on October 16, 2025 about DMD biomarkers?
How do the identified biomarkers affect DMD clinical trials for LNAI?
What sample size and platform were used in the LNAI‑linked proteomics study?
Which specific proteins did the study link to DMD progression in the LNAI announcement?
Are the prognostic biomarkers from the October 16, 2025 study ready for clinical use?
How did BioSymetrics (part of LNAI) contribute to the DMD proteomics study?
